%PDF-1.4
%
28 0 obj
<>
endobj
24 0 obj
<>
endobj
83 0 obj
<>stream
Acrobat Distiller 5.0 for Macintosh
2002-12-12T15:23:03Z
2024-03-28T16:16:32-07:00
2024-03-28T16:16:32-07:00
QuarkXPress. 4.11: AdobePS 8.7.2 (104)
application/pdf
Heather
2002-58.jan
uuid:f293d88d-1dd1-11b2-0a00-980927fd5800
uuid:f293d88f-1dd1-11b2-0a00-6a0000000000
endstream
endobj
13 0 obj
<>
endobj
14 0 obj
<>
endobj
29 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
91 0 obj
[94 0 R]
endobj
92 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
440 777 117 -27 re
f
54 54 m
558 54 l
S
BT
0 g
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:1)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(104)Tj
ET
1 g
109.5 58.85 395.97 -10.34 re
f
0.5 w
109.25 59.1 396.47 -10.84 re
S
BT
0 g
/T1_0 1 Tf
-0.00011 Tc 9.7 0 0 10 54 713.1616 Tm
(NOD2)Tj
/T1_1 1 Tf
0.2021 Tw 3.063 0 Td
(mutations associated with CD, while the remaining)Tj
-0.00369 Tw -3.063 -1.2 Td
(19% are due to 27 rare mutations)Tj
0.00079 Tc 0 Tw 6.3 0 0 6.5 182.5244 704.4616 Tm
(20)Tj
-0.00011 Tc -0.00369 Tw 9.7 0 0 10 188.8294 701.1616 Tm
(. Given the )Tj
/T1_0 1 Tf
0 Tw [-0.5 (post-hoc)]TJ
/T1_1 1 Tf
8.3438 0 Td
(power)Tj
0.0834 Tw -22.2437 -1.2 Td
(of our study and the strength \(LOD 4.7\) of the chromosome)Tj
0.0605 Tw 0 -1.2 TD
[(16q )54.9 (AS susceptibility locus)]TJ
0.0005 Tc 0 Tw 6.3 0 0 6.5 161.6452 680.4615 Tm
(8,9)Tj
-0.00011 Tc 0.0605 Tw 9.7 0 0 10 169.5264 677.1616 Tm
(, our results show that the most)Tj
-0.00349 Tw -11.9099 -1.2 Td
(common CD-associated )Tj
/T1_0 1 Tf
0 Tw [-0.3 (NOD2)]TJ
/T1_1 1 Tf
-0.00349 Tw 12.6805 0 Td
(mutations are not the basis for)Tj
0.0173 Tw -12.6805 -1.2 Td
[(the susceptibility locus for )54.8 (AS. )17.7 (This is significant because the)]TJ
/T1_0 1 Tf
0 Tw T*
(NOD2)Tj
/T1_1 1 Tf
0.21809 Tw 3.0789 0 Td
(mutations we investigated, unlike many other gene)Tj
0.04401 Tw -3.0789 -1.2 Td
(variants analyzed in association studies, have functional con-)Tj
0.1927 Tw T*
[(sequences af)17.7 (fecting monocyte-dependent responses through)]TJ
-0.0002 Tc 0 Tw T*
(NF-)Tj
/T1_2 1 Tf
0 Tc [-0.2 (\001)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.2524 Tw [0.2 (B activation in response to Gram negative bacteria)]TJ
0 Tc 0 Tw 6.3 0 0 6.5 288.4226 608.4615 Tm
(5)Tj
9.7 0 0 10 291.5751 605.1616 Tm
(.)Tj
-0.00011 Tc 0.0556 Tw -24.4923 -1.2 Td
(Similarly to CD, a link of immune response to enteric bacte-)Tj
0.21291 Tw T*
[(ria and )54.8 (AS has been proposed)]TJ
0.00079 Tc 0 Tw 6.3 0 0 6.5 179.3422 584.4615 Tm
(21)Tj
-0.00011 Tc 0.21291 Tw 9.7 0 0 10 185.6472 581.1616 Tm
(. Lack of influence of the)Tj
/T1_0 1 Tf
0 Tw -13.5719 -1.2 Td
(NOD2)Tj
/T1_1 1 Tf
0.0555 Tw 2.9163 0 Td
[(mutations on )54.9 (AS indicates that enteric bacteria do not)]TJ
0.283 Tw -2.9163 -1.2 Td
[(act in the same way in both diseases. Dif)17.7 (ferences might)]TJ
0.0127 Tw T*
(include the bacteria involved, the type of response elicited, or)Tj
0.02499 Tw T*
[(the absence of this kind of trigger for )54.8 (AS.)]TJ
0.1611 Tw 1.2371 -1.2 Td
(Coincident mapping of susceptibility loci as a guide for)Tj
0.0433 Tw -1.2371 -1.2 Td
[(selecting a candidate gene for the chromosome 16q )54.8 (AS locus)]TJ
0.01601 Tw T*
(has not been successful. )Tj
/T1_0 1 Tf
0 Tc 0 Tw 9.9211 0 Td
(A)Tj
-0.00011 Tc 0.859 0 Td
(priori)Tj
/T1_1 1 Tf
0.01601 Tw [-0.1 (, a specific cluster of suscep-)]TJ
0.1059 Tw -10.7801 -1.2 Td
(tibility loci could be due to a single gene underlying all the)Tj
0.0663 Tw T*
(loci, a cluster of functionally or evolutionarily related genes,)Tj
0.05769 Tw T*
[(each playing a role in dif)17.7 (ferent diseases, or to poor precision)]TJ
0 Tw T*
(mapping)Tj
0.0004 Tc 6.3 0 0 6.5 87.9453 452.4616 Tm
(1-3)Tj
-0.00011 Tc 0.1487 Tw 9.7 0 0 10 96.3483 449.1616 Tm
(. Either of the latter 2 alternatives might explain)Tj
0.02499 Tw -4.3658 -1.2 Td
(our results.)Tj
-0.0284 Tw 1.2371 -1.16 Td
[(Finally)64.8 (, our results point to the weakness of reasoning from)]TJ
0.01241 Tw -1.2371 -1.16 Td
(clinical or pathogenic similarities, or even from coinheritance)Tj
0.02409 Tw 0 -1.16 TD
[(in families, as guides to genetic investigation. )54.9 (Although these)]TJ
-0.0217 Tw T*
(features are still appealing and indicate a genetic link, our cur-)Tj
0.254 Tw T*
(rent understanding of disease mechanisms does not allow)Tj
0.0547 Tw T*
[(sound inferences about specific genetic factors. )17.6 (The similari-)]TJ
0.21381 Tw T*
[(ties between )54.8 (AS and CD may be due to other pathogenic)]TJ
0.0448 Tw T*
[(mechanisms related to common susceptibility genes dif)17.7 (ferent)]TJ
-0.0002 Tc 0 Tw T*
(from )Tj
/T1_0 1 Tf
-0.00011 Tc 2.227 0 Td
(NOD2)Tj
/T1_1 1 Tf
0.0336 Tw 2.8945 0 Td
(or to other unexplored )Tj
/T1_0 1 Tf
0 Tw 9.2978 0 Td
(NOD2)Tj
/T1_1 1 Tf
-0.02119 Tw 2.8945 0 Td
[(mutations. A)-228.7 (simi-)]TJ
0.10519 Tw -17.3137 -1.16 Td
(lar interpretation could be given to the recent description of)Tj
-0.0361 Tw T*
(the lack of association of one of the )Tj
/T1_0 1 Tf
0 Tw 14.2049 0 Td
(NOD2)Tj
/T1_1 1 Tf
2.8247 0 Td
(variants, )Tj
/T1_0 1 Tf
0 Tc 3.6289 0 Td
(3020insC)Tj
/T1_1 1 Tf
[0.2 (,)]TJ
-0.00011 Tc 0.03391 Tw -20.6585 -1.16 Td
(with susceptibility to psoriasis, another of the diseases with a)Tj
0.21159 Tw T*
(susceptibility locus in the same region of chromosome 16)Tj
0.02499 Tw T*
(sharing pathogenic and clinical features with CD)Tj
0.00079 Tc 0 Tw 6.3 0 0 6.5 245.0671 278.0618 Tm
(22)Tj
0 Tc 9.7 0 0 10 251.3721 274.7618 Tm
(.)Tj
-0.00011 Tc 0.1109 Tw -20.3476 -2.32 Td
(Note added in proof: Since submission of this manuscript 2)Tj
0.1284 Tw T*
(studies have been published reporting similar results on the)Tj
0.058 Tw T*
(same 3 )Tj
/T1_0 1 Tf
0 Tw [-0.2 (NOD2)]TJ
/T1_1 1 Tf
0.058 Tw 6.0892 0 Td
[(mutations in )54.8 (AS: Crane )54.8 (AM, Bradbury L, van)]TJ
0.15739 Tw -6.0892 -1.16 Td
(Heel DA, et al. Role of )Tj
/T1_0 1 Tf
0 Tw [-0.4 (NOD2)]TJ
/T1_1 1 Tf
0.1573 Tw 13.4584 0 Td
(variants in spondylarthritis.)Tj
0.3161 Tw -13.4583 -1.16 Td
(Arthritis Rheum 2002;46:1629-33; and Miceli-Richard C,)Tj
0.00391 Tc 0.371 Tw T*
(Zouali H, Lesage S, et al.)Tj
/T1_0 1 Tf
0.004 Tc 0 Tw 12.7475 0 Td
(CARD15/NOD2)Tj
/T1_1 1 Tf
0.00391 Tc 0.371 Tw 7.1686 0 Td
(analyses in)Tj
-0.00011 Tc 0.02499 Tw -19.9161 -1.16 Td
[(spondylarthropathy)64.8 (. )54.8 (Arthritis Rheum 2002;46:1405-6.)]TJ
/T1_3 1 Tf
0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/T1_1 1 Tf
-0.08501 Tc 7.76 0 0 8 54 147.9618 Tm
[(We)-79.9 ( )]TJ
-0.0051 Tc 0.0551 Tw 1.5979 0 Td
[(thank the patients and the staf)17.6 (f of the Rheumatology Unit at the Hospital)]TJ
0.00031 Tw -1.5979 -1.25 Td
[(Clinico Universitario de Santiago for their contribution. )17.5 (W)79.9 (e also thank Miguel)]TJ
-0.0267 Tw 0 -1.25 TD
[(Otero )54.8 (Adr\207n for his help in processing samples and Olfert Landt \(TIB Molbi\
ol,)]TJ
0.02499 Tw T*
(Berlin, Germany\) for designing the Light Cycler hybridization probes.)Tj
/T1_3 1 Tf
-0.00011 Tc 0 Tw 9.7 0 0 10 54 93.9618 Tm
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61 83.9618 Tm
[(1.)-875.1 (V)110.8 (yse )17.7 (TJ, )17.7 (T)69.9 (odd JA. Genetic analysis of autoimmune disease. Cell)]TJ
0 Tc 0 Tw 1.675 -1.25 Td
[(1996;85:31)36.9 (1-8.)]TJ
-0.00011 Tc 0.02499 Tw 31.325 80.0709 Td
[(2.)-875.1 (Becker KG, Simon RM, Bailey-W)39.7 (ilson JE, et al. Clustering of non-)]TJ
1.675 -1.25 Td
(major histocompatibility complex susceptibility candidate loci in)Tj
T*
[(human autoimmune diseases. Proc Natl )54.8 (Acad Sci USA)]TJ
0 Tc 0 Tw T*
(1998;95:9979-84.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.225 Td
[(3.)-875.1 (W)79.9 (andstrat )54.8 (A, )17.7 (W)79.9 (akeland EK. )17.7 (The genetics of complex autoimmune)]TJ
1.675 -1.225 Td
(diseases: non-MHC susceptibility genes. Nat Immun 2001;2:802-9.)Tj
-1.675 -1.225 Td
[(4.)-875.1 (Hugot JP)110.7 (, Chamaillard M, Zouali H, et al. )54.8 (Association of NOD2)]TJ
1.675 -1.225 Td
[(leucine-rich repeat variants with susceptibility to Crohn\325)54.8 (s disease.)]TJ
0 -1.225 TD
[(Nature 2001;41)36.8 (1:599-603.)]TJ
-1.675 -1.225 Td
[(5.)-875.1 (Ogura )36.8 (Y)128.9 (, Bonen DK, Inohara N, et al. )54.8 (A)-220.1 (frameshift mutation in)]TJ
1.675 -1.225 Td
[(NOD2 associated with susceptibility to Crohn\325)54.8 (s disease. Nature)]TJ
0 Tw T*
[(2001;41)36.8 (1:603-6.)]TJ
0.02499 Tw -1.675 -1.225 Td
[(6.)-875.1 (Hampe J, Cuthbert )54.8 (A, Croucher PJ, et al. )54.8 (Association between)]TJ
1.675 -1.225 Td
[(insertion mutation in NOD2 gene and Crohn\325)54.8 (s disease in German)]TJ
T*
(and British populations. Lancet 2001;357:1925-8.)Tj
-1.675 -1.225 Td
[(7.)-875.1 (Brown MA, Laval SH, Brophy S, Calin )54.8 (A. Recurrence risk)]TJ
1.675 -1.225 Td
(modelling of the genetic susceptibility to ankylosing spondylitis.)Tj
0 Tc T*
(Ann Rheum Dis 2000;59:883-6.)Tj
-0.00011 Tc -1.675 -1.225 Td
[(8.)-875.1 (Brown MA, Pile KD, Kennedy LG, et al. )54.8 (A)-220.1 (genome-wide screen)]TJ
1.675 -1.225 Td
[(for susceptibility loci in ankylosing spondylitis. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1998;41:588-95.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.225 Td
[(9.)-875.1 (Laval SH, )17.7 (T)35 (imms )54.8 (A, Edwards S, et al. )17.7 (Whole-genome screening in)]TJ
1.675 -1.225 Td
(ankylosing spondylitis: evidence of non-MHC genetic-)Tj
T*
[(susceptibility loci. )54.8 (Am J Hum Genet 2001;68:918-26.)]TJ
-2.175 -1.225 Td
[(10.)-875.1 (Smale S, Natt RS, Orchard )17.7 (TR, Russell )54.8 (AS, Bjarnason I.)]TJ
2.175 -1.225 Td
[(Inflammatory bowel disease and spondyloarthropathy)64.8 (. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2001;44:2728-36.)Tj
-0.0369 Tc 0 Tw -2.1381 -1.225 Td
[(11)-36.9 (.)]TJ
-0.00011 Tc 0.02499 Tw 2.0881 0 Td
[(Gravallese EM, Kantrowitz FG. )54.8 (Arthritic manifestations of)]TJ
0.05 -1.225 Td
[(inflammatory bowel disease. )54.8 (Am J Gastroenterol 1988;83:703-9.)]TJ
-2.175 -1.225 Td
[(12.)-875.1 (Orchard )17.7 (TR, )17.7 (W)79.9 (ordsworth BP)110.7 (, Jewell DP)110.8 (. Peripheral arthropathies in)]TJ
2.175 -1.225 Td
(inflammatory bowel disease: their articular distribution and natural)Tj
0 Tc T*
[(history)64.9 (. Gut 1998;42:387-91.)]TJ
-0.00011 Tc -2.175 -1.225 Td
[(13.)-875.1 (Brophy S, Pavy S, Lewis P)110.7 (, et al. Inflammatory eye, skin, and)]TJ
2.175 -1.225 Td
(bowel disease in spondyloarthritis: genetic, phenotypic and)Tj
T*
(environmental factors. J Rheumatol 2001;28:2667-73.)Tj
-2.175 -1.225 Td
[(14.)-875.1 (Bollow M, Fischer )17.7 (T)74 (, Reisshauer H, et al. Quantitative analyses of)]TJ
2.175 -1.225 Td
[(sacroiliac biopsies in spondyloarthropathies: )17.7 (T)-257.1 (cells and)]TJ
T*
(macrophages predominate in early and active sacroiliitis- cellularity)Tj
T*
(correlates with the degree of enhancement detected by magnetic)Tj
0 Tc T*
[(resonance imaging. )54.8 (Ann Rheum Dis 2000;59:135-40.)]TJ
-0.00011 Tc -2.175 -1.225 Td
[(15.)-875.1 (Bur)17.7 (gio )17.7 (VL, Fais S, Boirivant M, Perrone )54.8 (A, Pallone F)79.7 (. Peripheral)]TJ
2.175 -1.225 Td
[(monocyte and naive )17.7 (T)91.8 (-cell recruitment and activation in Crohn\325)54.8 (s)]TJ
T*
(disease. Gastroenterology 1995;109:1029-38.)Tj
-2.175 -1.225 Td
[(16.)-875.1 (T)69.9 (a)0.3 (r)17.7 (gan SR, Hanauer SB, van Deventer S, et al. )54.8 (A)-220.1 (short-term study)]TJ
2.175 -1.225 Td
(of chimeric monoclonal antibody cA2 to tumor necrosis factor)Tj
T*
[(alpha for Crohn\325)54.8 (s disease. Crohn\325)54.8 (s Disease cA2 Study Group. )]TJ
0 Tc T*
(N Engl J Med 1997;337:1029-35.)Tj
-0.00011 Tc -2.175 -1.2375 Td
[(17.)-875.1 (Baeten D, Kruithof E, van den Bosch F)79.7 (, et al. Immunomodulatory)]TJ
2.175 -1.2375 Td
[(ef)17.7 (fects of anti-tumor necrosis factor alpha therapy on synovium in)]TJ
0 -1.2375 TD
(spondylarthropathy: histologic findings in eight patients from an)Tj
T*
[(open-label pilot study)64.8 (. )54.8 (Arthritis Rheum 2001;44:186-95.)]TJ
-2.175 -1.2375 Td
[(18.)-875.1 (van der Linden S, )17.7 (V)110.8 (alkenbur)17.7 (g HA, Cats )54.8 (A. Evaluation of diagnostic)]TJ
2.175 -1.2375 Td
[(criteria for ankylosing spondylitis. )54.8 (A)-220.1 (proposal for modification of)]TJ
T*
[(the New )36.8 (Y)99.8 (ork criteria. )54.8 (Arthritis Rheum 1984;27:361-8.)]TJ
-2.175 -1.2375 Td
[(19.)-875.1 (Collado-Escobar MD, Nieto )54.8 (A, Mataran L, Raya E, Mart\222n J.)]TJ
2.175 -1.2375 Td
(Interleukin 6 promoter polymorphism is not associated with)Tj
T*
(ankylosing spondylitis. J Rheumatol 2000;27:1461-3.)Tj
-2.175 -1.2375 Td
[(20.)-875.1 (Lesage S, Zouali H, Cezard JP)110.7 (, et al. CARD15/NOD2 mutational)]TJ
2.175 -1.2375 Td
(analysis and genotype-phenotype correlation in 612 patients with)Tj
T*
[(inflammatory bowel disease. )54.8 (Am J Hum Genet 2002;70:845-57.)]TJ
-2.175 -1.225 Td
[(21.)-875.1 (Sieper J, Braun J. Pathogenesis of spondylarthropathies. Persistent)]TJ
2.175 -1.225 Td
[(bacterial antigen, autoimmunity)64.8 (, or both? )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw 0 -1.225 TD
(1995;38:1547-54.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.225 Td
[(22.)-875.1 (Nair RP)110.7 (, Stuart P)110.7 (, Ogura )36.8 (Y)128.9 (, et al. Lack of association between)]TJ
2.175 -1.225 Td
(NOD2 3020InsC frameshift mutation and psoriasis. J Invest)Tj
T*
[(Dermatol 2001;1)36.8 (17:1671-2.)]TJ
ET
1 g
438 770 120 -25 re
f
BT
0 g
/T1_4 1 Tf
0 Tw 20.37 0 0 21 472.1481 753.6089 Tm
(2002-58-3)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS1 gs
/T1_5 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS1 gs
/T1_6 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS1 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS1 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
32 0 obj
<>
endobj
41 0 obj
<>
endobj
49 0 obj
<>
endobj
7 0 obj
<>
endobj
34 0 obj
<>
endobj
76 0 obj
<>
endobj
87 0 obj
<>
endobj
35 0 obj
<>
endobj
37 0 obj
<>
endobj
31 0 obj
<>stream
HTMo
;@.a&)8] gy_;Ϡh8C{q"{p4ۡ
xfvisO}v5:?|Rb3d^Ns^As_p EZWZ'Sdk0
M=Hű_mTr2(;-qLLASPfY&jq# ɉU LɇJd'sU__YNjC}"THԏ